Syndax Pharmaceuticals (NASDAQ:SNDX) has emerged as a focal point in biotech after FDA approval of its lead product Revuforj (revumenib) in October 2025. The company successfully transitioned from development to commercial operations.
In January 2026, Syndax preannounced Q4 sales figures that exceeded consensus estimates. The strong commercial debut demonstrated market acceptance and effective execution. The stock has delivered an 89% return over the past year, trading at $20.13.
Despite strong momentum, Syndax continues to operate at a loss. EPS was -$2.79 for the last twelve months, but revenue surged 397% to $217 million. Analysts anticipate sales growth and six analysts have revised earnings upwards.
Revuforj treats relapsed/refractory NPM1-mutated AML. The company also develops axatilimab for graft-versus-host disease, diversifying beyond hematologic malignancies.
Market cap stands at $1.8 billion. Analysts assign a 70% probability to positive data from ongoing first-line combination studies. Success could expand the addressable patient population significantly. The competitive landscape includes multiple targeted therapies for AML subtypes.
